LENSAR is an Orlando cataract-laser company whose public residual is a claim on a working procedure engine after Alcon walked away from a blocked sale. The tape near $7 and a mid-eighties-million equity value prices a rebuilt independent franchise, not the takeout that died in March. Common sits behind preferred stock, a still-large warrant liability, and a cash pile that is already thinner than year-end.
The most important recent development is the second-quarter rebound after merger limbo, not the reported swing to profit. Procedure fees and lease-plus-service income carried most of the print, and utilization on the installed ALLY robotic systems did the real work. System placements recovered from the first-quarter stall, yet they remain well below last year's placement pace. That gap is the entire commercial question.
The tension is that headline earnings are not the franchise. Half-year net income is dominated by the kept Alcon deposit and a non-cash collapse in warrant fair value. Operating cash still went out the door in the first half, inventories are heavy, and selling costs sit at a lean level that management already flags as temporary. A one-time tariff refund also flattered gross profit.
What decides the residual is whether ALLY placements rebuild toward the mid-teens while procedure volume keeps compounding on the base already in the field. If placements stay near the post-termination trickle, the equity is a thin option on a cash clock. If the channel recovers without another preferred or warrant reset, the current multiple is a fair price for a still-small recurring book.